Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gynecology | Internal Medicine | Nursing | Oncology | Journal

Back to Journal Articles

Bisphosphonates, Annual BMD Screen Up Fracture Prevention

Last Updated: February 29, 2012.

 

Cost-effective for preventing fractures in postmenopausal women with HR+ breast cancer

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In a hypothetical model of postmenopausal women receiving adjuvant aromatase inhibitors for hormone receptor-positive early breast cancer, baseline and annual bone mineral density screening followed by selective treatment with oral bisphosphonates for those diagnosed with osteoporosis is a cost-effective strategy, according to a study published online Feb. 27 in the Journal of Clinical Oncology.

WEDNESDAY, Feb. 29 (HealthDay News) -- In a hypothetical model of postmenopausal women receiving adjuvant aromatase inhibitors (AIs) for hormone receptor (HR)-positive early breast cancer (EBC), baseline and annual bone mineral density (BMD) screening followed by selective treatment with oral bisphosphonates for those diagnosed with osteoporosis is a cost-effective strategy, according to a study published online Feb. 27 in the Journal of Clinical Oncology.

Kouta Ito, M.D., of Brigham and Women's Hospital in Boston, and colleagues developed a Markov state transition model to simulate clinical practice and outcomes in a hypothetical cohort of women aged 60 years with HR-positive EBC starting a five-year course of AI therapy following primary surgery for breast cancer. The following strategies were compared: no intervention; one-time BMD screening and selective bisphosphonate therapy in women with osteoporosis or osteopenia; annual BMD screening and selective bisphosphonate therapy in women with osteoporosis or osteopenia; and universal bisphosphonate therapy.

The researchers found that the incremental cost-effectiveness ratio for annual BMD screening followed by oral bisphosphonates for those with osteoporosis was $87,300 per quality-adjusted life-year (QALY) gained; annual BMD screening followed by oral bisphosphonates for those with osteopenia was $129,300 per QALY gained; and universal treatment with oral bisphosphonates was $283,600 per QALY gained. One-time BMD screening followed by oral bisphosphonate therapy for those with osteoporosis or osteopenia was dominated. The results were sensitive to age at the initiation of AI therapy, type of bisphosphonates, post-treatment residual effect of bisphosphonates, and a potential adjuvant benefit of intravenous bisphosphonates.

"In postmenopausal women receiving adjuvant AIs for HR-positive EBC, a policy of baseline and annual BMD screening followed by selective treatment with oral bisphosphonates for those diagnosed with osteoporosis is a cost-effective use of societal resources," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial

Copyright © 2012 HealthDay. All rights reserved.


Previous: Despite Benefits of Selenium, Supplements May Be Harmful Next: Ruxolitinib Reduces Spleen Size in Myelofibrosis

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.